Feb 6, 2024
Shenandoah Oncology’s Dr. Rich Ingram Testifies in Support of Prohibiting White-Bagging Mandates
On February 6th, Dr. Rich Ingram from Shenandoah Oncology gave virtual testimony on behalf of the Virginia Association of Hematologists and Oncologists (VAHO) in support of VA HB 1006 in the Virginia House of Delegates Labor and Commerce Subcommittee #1. This bill extends Virginia’s Patient Choice in Pharmacy laws to protect a patient’s right to choose where they access their infusion medications- allowing patients to reject white bagging, brown bagging, and home infusion policies at their discretion.
Bill Text: HB 1006
Feb 6, 2024
Compass Oncology’s Dr. David Cosgrove and WVCI’s Dr. Matthew Lonergan Testify in Support of Protecting Patient Access to Timely Care
On February 6th, Dr. David Cosgrove from Compass Oncology, Dr. Matthew Lonergan from WVCI, and Dr. Bud Pierce from Oregon Oncology Specialists testified in support of HB 4012 during a committee hearing of Oregon House Committee on Behavioral Health and Health Care. HB 4012 protects patients access to high quality oncology care by prohibiting insurance companies and PBMs from mandating that patients receive their physician administered drug from payer’s specialty pharmacies in the physician office setting.
Their goal was to emphasize the adverse effects of white bagging on patient care and cancer treatment, which include:
- Delay in care
- Creating drug waste
- Increasing patient costs
- Threats to drug supply chain integrity
- Threats to practice viability
It is our hope that the House committee continues to work on passing HB 4012 during their upcoming working committee sessions. Testimony from the physician starts at 1:34:00.
Oct 19, 2023
Debra Patt, MD, PhD, MBA
Dr. Debra Patt, MD, PhD, MBA, with Texas Oncology testified before the House Energy and Commerce Committee. She discussed the pressing need to enhance patient access to healthcare and streamline administrative processes for physicians. She highlighted the risks associated with ongoing reductions in Medicare fee schedules and their detrimental effects on patient care. She also shed light on the challenges posed by the 340B program, staffing shortages, and the continued efforts of restoring screening levels to pre-COVID-19 standards.
May 17, 2023
Debra Patt, MD, PhD, MBA
Debra Patt, MD, with Texas Oncology, testifies before the Energy and Commerce Health Subcommittee Hearing on The Obama Administration’s Medicare Drug Experiment: The Patient and Doctor Perspective.
May 10, 2023
Debra Patt, MD, PhD, MBA
HB 1647/SB 1138, Dr. Debra Patt Senate Testimony of Texas white-bagging bill (starts at 21:47 ish)
Mar 29, 2023
Diaa Osman, MD
Diaa Osman, MD, with Texas Oncology, testifies before the Texas Senate Health and Human Services Committee on policy that would require health benefit plans to provide coverage for biomarker testing
Mar 28, 2023
Gury Doshi, MD
Gury Doshi, MD, with Texas Oncology, testifies before the Texas House Insurance Committee on legislation that prohibits insurers and PBMs from requiring the patient receive their physician administered drugs via white-bagged. from a PBM/insurer owned or affiliated specialty pharmacy.
Mar 17, 2023
Rupesh Parikh, MD
Rupesh Parikh, MD, with Comprehensive Cancer Centers of Nevada, testifies before the Assembly Committee on Health and Human Services in support of policy that would require health benefit plans to provide coverage for biomarker testing.
Mar 14, 2023
Les Busby, MD
Les Busby, MD, with Rocky Mountain Cancer Centers, testifies before the Colorado House Health & Insurance Committee on legislation that grants the commissioner of insurance the power to enforce prohibitions and requirements on Pharmacy Benefit Managers (PMBs) and the ability to impose penalties on PBMs that fail to comply with the law.
Mar 8, 2023
Kash Firozvi, MD
Kash Firozvi, MD, with Maryland Oncology Hematology, testifies before the Insurance and Pharmaceuticals Subcommittee on proposed anti-steering legislation.
Feb 8, 2023
Scott Rushing, MD
Scott Rushing, MD, with Compass Oncology, testifies before the Oregon Senate Committee on Finance and Revenue in support of legislation that would exempt receipts from the administration or dispensing of medication in a clinical setting other than a hospital, like Compass Oncology, from the corporate activity tax.
Feb 9, 2022
Randy Drosick, MD
Randy Drosick, MD, with OHC Specialists in Cancer and Blood Disorders in Ohio, testifies before the Ohio House Insurance Committee in support for HB 451: Revising the Physician Administered Drug Law.
Mar 9, 2021
Debra Patt, MD, PhD, MBA
Debra Patt, MD, with Texas Oncology, testifies before the Texas House Insurance Committee on How Prior Authorization Costs Patients Time & Money.
Jul 11, 2018
Debra Patt, MD, PhD, MBA with Texas Oncology testifies before the Energy and Commerce Health Subcommittee Hearing on Opportunities to Improve the 340B Drug Pricing Program.
Debra Patt, MD, with Texas Oncology testifies before the Energy and Commerce Health Subcommittee Hearing on Opportunities to Improve the 340B Drug Pricing Program.
May 21, 2014
Barry Brooks, MD with Texas Oncology, testifies before the Energy and Commerce Health Subcommittee Hearing on Keeping the Promise: Site of Service Medicare Payment Reforms.
Barry Brooks, MD, with Texas Oncology, testifies before the Energy and Commerce Health Subcommittee Hearing on Keeping the Promise: Site of Service Medicare Payment Reforms.